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ABSTRACT

Title: To study Disease Activity and various Counseling techniques in Rheumatoid Arthritis
patients.
Background: Education and counseling creates awareness amongst RA patients regarding the
nature of their disease, drugs and lifestyle. Often, early diagnosis of RA prevents permanent
disability. However, this does not happen in many cases. With the intention of coping with RA
related complications and promoting healthy living, this study assessed the importance of
counseling interventions with the aid of patient information leaflets and digital media as an
adjunct for better patient care.
Objectives: To study three counseling interventions, drug utilization, disease activity and quality
of life in Rheumatoid Arthritis patients.
Methods: A prospective study was conducted where 30 patients were enrolled based on the
inclusion and exclusion criteria of the study. The patients were randomly grouped into three
categories by simple randomization using Quickcals- Graphpad software. After seeking the
informed consent and providing participant information sheets, each group was given a different
counseling technique with the aid of expert validated leaflets. Pre and post assessment of
patient’s knowledge regarding their condition was determined by administering the same
questionnaire before and after the counseling session. Each session was completed within 10-15
minutes depending upon the co-operation and comprehension exhibited. A health assessment
questionnaire was also administered during and after 3 months of hospitalization to assess the
functional capacity of the patients.

Results: Various demographic parameters like age, sex, occupation, education, co morbidities,
duration of RA, disease activity and physical disability were evaluated. Among n=30 patients,
most patients fell under the age group of 51-70 years (46.7%). 3 (10%) were male and 27 (90%)
were female. Out of n=30 patients,20(66.7%) patients were housewives and 9 (30%), were
illiterate. The duration of RA for most of the patients were between 3-5 years. (26.7%). 2 male
patients and 14 female patients tested positive for rheumatoid factor. Mean DAS28 was found to
be 5.64 ± 1.65 and 17 (56.7%) patients fell under high disease activity. Mean HAQ was found to
be 1.18 ± 0.87 and mean VAS score was 55.67 ± 27.50. MTX was widely prescribed (n=16,
53.3%) as monotherapy or in combination with other DMARDs followed by HCQ(n=15 50%).
Among combination therapy MTX+HCQ combination was preferred over other combinations and
was given in 7(23.3%) patients followed by HCQ+MTX+SSZ combination in 6(20%) patients.
Group C demonstrated a greater improvement in understanding and decrease in pain scores in
comparison to other groups post counseling where as Group B showed greater difference in HAQ
scores.
Conclusion: The study demonstrated that pharmaceutical care counseling with the aid of leaflets
and SMS reminders were well received by the patients resulting in improved understanding
regarding their condition as well as improvement in the pain and HAQ scores. Majority of
patients fell under high disease activity and MTX was widely prescribed as monotherapy.
Among combination therapy MTX+HCQ combination was preferred over other combinations.
2
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1. INTRODUCTION
Definition
Rheumatoid arthritis (RA) is an autoimmune disease persisting for a long time that affects
bilateral small joints, progressing to bilateral larger joints, and eventually the skin, eyes, heart,
kidneys, and lungs. This damages the bone and cartilage of joints, and weakens the tendons and
ligaments causing joint deformities and bone erosion. (1)
Signs and Symptoms
Typical symptoms of RA include morning stiffness lasting more than 30 minutes, tender,
swollen joints, fatigue, fever, weight loss, and rheumatoid nodules. (2)
Risk factors
 Age: Most people are diagnosed between the ages of 40 and 60. (3)
 Sex: Women are more prone to RA than men.(3)


Genetics: The risk of RA is highest when people with human leukocyte antigen class II
genotypes genes are exposed to environmental factors like smoking or when a person is
overweight.(3)

 Obesity: Overweight individuals have a significantly greater chance of developing RA in
comparison to a healthy weight individual.(3)
 Smoking: Cigarette smoking increases the risk of developing RA. (3)

Diagnosis
The progression of RA can be slowed down by diagnosing the disease and initiating the
treatment early which aids in preventing joint erosions. History and physical examination of the
patient enables to diagnose RA. Clinical findings are the mainstay in selecting the appropriate
laboratory test for the confirmation or ruling out of the disease.Abnormal values of laboratory
tests like Rheumatoid factor (RF), Erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), Anti-citrullinated protein antibody test (anti-CCP) and Antinuclear antibody test are most
typical features of RA. The anatomic changes in RA patients such as joint space narrowing and
erosions can be investigated by means of plain radiography, sonography and MRI. (4)
1.4.1 Diagnostic criteria
The criteria recommended by American College of Rheumatology in 2010 for diagnosing RA is
as follows:(5)

4

CRITERIA
A. Joints
1 large joint
2-10 large joints
1-3 small joints
4-10 small joints
>10 joints

SCORE
0
1
2
3
5

B. Serology
Negative RF and negative anti-CCP
Low positive RF or low positive ACPA
High positive RF or high positive ACPA

0
2
3

C. Acute phase reactants
Normal CRP and ESR
Abnormal CRP or ESR

0
1

D. Symptom duration
<6 weeks
>6 weeks

0
1

Table 1: RA Classification Criteria - ACR/EULAR 2010
Treatment
Both pharmaceutical and non-pharmaceutical therapies aid in symptomatic management of RA
and disease modification.(6)
1.5.1 Pharmacologic Therapy

Non Steroidal anti-inflammatory drugs (NSAIDs) aim to alleviate pain and decrease
inflammation. Common examples include acetylsalicylate, naproxen, and ibuprofen that are
available over-the-counter from pharmacies. If NSAIDS are ineffective, Corticosteroids are
generally recommended. They work by reducing pain and inflammation, as well as delaying joint
damage. However, serious side effects such as cataracts, osteoporosis, glaucoma, obesity and
diabetes mellitus may occur due to prolonged usage of corticosteroids. Tapering the doses
gradually may reduce side effects and improve a patient’s condition. (1)
Promoting remission is the major goal of RA treatment. This is achieved by Disease-modifying
antirheumatic drugs (DMARDs) which work by blocking the body’s immune system and
therefore delaying the progression of joint damage.Examples include leflunomide, methotrexate,
sulfasalazine, and hydroxychloroquine. These medications take several weeks to months to be
effective. (1)
5

A treat-to-target strategy should be used:(7)
 Low disease activity: DMARD monotherapy over double or triple therapy; Methotrexate is
the preferred DMARD.
 Moderate or high disease activity: DMARD monotherapy over double or triple therapy.
 Moderate or high disease activity despite DMARD monotherapy: Combination
DMARDs or a tumor necrosis factor (TNF) inhibitor or a non-TNF biologic agent is
preferred.
1.5.2 Non Pharmacologic therapy
Non pharmacologic treatment is often recommended in addition to the pharmacologic therapies
in patients with RA. Education, Guidance and support is vital for majority of patients so as to
tackle the outcomes of the disease. Non-drug care includes healthy eating, daily movement,
warm and cold treatments, balancing activity with rest, stress reduction, positive attitude and
support system. (8,9)
Tools to monitor Disease Progression
Disease Activity Score
Disease activity in RA patients is determined using the DAS-28. It is used as a guide in the
suppression of RA disease activity with DMARDs. A blood sample is taken from the patient for
the assessment of ESR levels. In addition, tender and swollen joint counts are determined. A
general health assessment score is obtained using a visual analog scale. (9)
DAS-28 is then calculated using a programmed calculator or computer. The scores obtained
allow the classification of patients into: (10)
 Remission (0 - <2.6),
 Low disease activity (2.6 - 3.2),
 Moderate disease activity (3.2-<5.1)
 High disease activity (>5.1).
Joint score:
 Tender joints (0-28)
 Swollen joints (0-28)
Measures:
 ESR (mm/first hour)
 General health (0-100)
Score:
Table 2: The DAS-28 Calculator – Rheumakit

6

1.6.2 The Stanford Health Assessment Questionnaire (HAQ)
Among the first Patient Reported Outcome (PRO) instrument was HAQ, published in 1980.It is a
widely used generic instrument that collects data on five patient centered health criteria’s:
avoiding disability; relieving pain and discomfort; avoiding treatment adverse effects; keep
healthcare costs low and prevent death.(11-12)
The HAQ-Disability index (HAQ-DI) is a 2 page HAQ comprised of 20 questions, divided in 8
categories to assess the functional capacity of the patient such as dressing/grooming, arising,
reach, grip, walking, eating, hygiene, and daily activities. The response is divided into 4 levels
for each question and is scored from 0 to 3, (11-12)
 0 = without any difficulty
 1 = with some difficulty
 2 = with much difficulty
 3 = unable to do.
An aids or devices variable for each question is used to record the type of assistance required by
the patient which lead to an increase in the score. The aids used include: dressing devices, special
chairs, special utensils, canes, walkers, crutches, raised toilet seats, bathtub seats, bathtub bars
and long handled appliances in bathroom, long handled appliances for reaching and jar openers
for previously opened jars. The mean score calculated ranges from:
 0 to 1 = mild to moderate difficulty
 1 to 2 = moderate to severe disability
 2 to 3 = severe to very severe disability.(11-12)
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2. NEED FOR STUDY
Rheumatoid Arthritis (RA) affects nearly 1% of the adult population globally. (13)India is a
subcontinent with the second largest population worldwide and a socio cultural diversity that
includes 20 official languages. Understanding the impact on RA on the population is necessary to
come up with techniques for disease management. A study focused on the disease activity and
quality of life of the population will increase the knowledge of disease burden RA presents in
India.(14)
RA has been shown to have a higher incidence on people with low income and less education.
RA has a significant impact in quality of life of patients and when it is left uncontrolled it is
shown to decrease the quality of life of the patient and increase complications. Disease activity
and the damage it causes to the joints are not enough to judge the impact it has on individuals.
Quality of life assessment in RA provides the needed information on drug therapy for a longterm outcome.(15)
2.1 Patient education in RA
Owing to the complex nature of RA not one particular course of treatment has shown to be
consistently effective. Patient education is one major area, which can improve the patient’s
quality of life. The personal need and belief of the patient must be addressed while developing a
patient education program. This depends on the history of disease and experience of the patient
with the health care professional. Work in the field of adult education has shown that an
interactive method of learning approach is more successful and acceptable than an instructive
style. This has been observed in chronic kind of diseases and also arthritis. (16)
Patients that received information leaflets from their healthcare professionals have shown more
adherences to their medication. PILs can reduce anxiety about their condition and can contribute
to a better outcome of illness in better-informed patients.
A recent evaluation of leaflets distributed by Arthritis and Rheumatism Council shows that for
people with rheumatoid arthritis who received a PIL, the report states that “there was an increase
in knowledge patients had of their condition, there was an associated decrease in pain and there
was an associated decrease in depression”. (17) The report also reminds us that better educated
patients are able to participate more actively in their own treatment.
2.2 SMS Reminders
The fact that mobile phone ownership is high across the world and that people carry their phones
with them almost all the time makes the mobile phones feasible tools for frequent data
assessments. A high percentage of patients up to age 65 were successfully using SMS despite
older age or functional disability caused by rheumatic diseases. From the clinician and
researcher’s point of view, the SMS method is very feasible. The SMS method may lead to a
reduction in data management burden, processing time and costs. (18)
9

2.3 Challenges
Patients who are affected with RA experience chronic pain and suffering, deformities, disabilities
to their fingers and joints. It is important to identify the availability of effective therapies so that
inflammation, joint destruction and disability can be prevented. (19)
RA has a major impact in health related quality of life. This increases the health related costs and
mortality of the patients when compared to the healthy population. There is an increased
economic burden in the country as the patients are unable to work and are dependent on the state
for the health and social welfare services. This makes it important to have educational programs
to facilitate early diagnosis and proper management of RA. Many studies have shown early
treatment can reduce the long-term disability, prevent joint damage and this can help the patients
to maintain their functional independence.(19)
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3. AIMS AND OBJECTIVES:
1. Primary Objective: To study three counseling interventions
GROUP 1
CONTROL GROUP
Standard care in the
hospital as part of
standard procedure



Counselling by
consultant doctor
and the nurse
General drug leaflet

GROUP 2
Pharmaceutical care
counselling
(Drugs, Disease, Lifestyle)

GROUP 3
Pharmaceutical care
counselling (Drugs, Disease,
Lifestyle)
Digital media Notifications




One to One counselling by
clinical pharmacist
Drugs, Disease, Lifestyle
Leaflets





One to One Counselling,
SMS reminders by clinical
pharmacist
Drugs, Disease, Lifestyle
Leaflets
Text message Reminders

Table 3: Various counseling groups
2. Secondary Objective: To study drug utilization and disease activity and quality of life in
rheumatoid arthritis patients.
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4. REVIEW OF LITERATURE
Patient education plays a major role in completing clinical care. Importance of patient education
in clinical care includes facilitating the patients to play a vital role in their disease management
and to enhance their coping with the disease, including limited demands for the health care
system. The importance of patient education increases with the prevalence of the chronic illness.
The better informed the patient the easier it is to limit the predisposing factors and managing the
illness. (20)
Patients who are diagnosed with chronic and complex diseases find information regarding their
illness and medication very beneficial. Patient self-care is important when it comes to the longterm management of their diseases. Several studies have shown that due to lack of information
about the disease, patients were unable to manage their disease. The efficient management of RA
comprises of a huge component of self-care, and this demands a level of knowledge that some
patients gain with extra information. Various studies have shown widespread lack of education in
patients diagnosed with RA, and patients themselves do not think they gain all the information
they require. (21)
In case of arthritis, which has to be managed throughout the life, patient education improves
behavior and knowledge as well as physical and psychosocial health status. An important part of
this education involves teaching the patient necessary skills to manage the disease on a daily
scale. This allows the patient to adjust to their medications and have skills to self-adjust to
lifestyle to manage the disease. (22)
The aim of patient education programs have shown a wide spectrum of variation due to the
complex nature of RA and its management, and because of no course of treatment alone has
proven to be effective in a consistent manner. Some of the major areas considered are drugs,
physical activity and lifestyle, nutrition, disease process and medical management,
communication with doctors and family and stress management. The content of information
given to the patient should comply with the belief and needs of the patient whose is receiving the
information. (16)
Increase in level of patient knowledge can be achieved through written educational material,
which is frequently used in clinical settings to aid verbal information. This gives a sense of
reassurance to the patient. (23)
Certain studies show an improvement in knowledge in osteoarthritis patients with the use of
leaflets. Barlow J et al found in his study that receiving PILs that have disease related
information caused no negative psychological distress to the patients. This gives evidence to how
receiving information does more good than harm. The study also found that there are outcomes
that are more positive when the PILs are given by hand through a physician or pharmacist than
be sent through mail. If the information delivered to the patient is specific to the disease
progression, the patient’s interest to know about the disease condition will not decline over
time.(23)
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Research has shown that qualities required for preparing a patient information leaflet (PIL) are
that language should be simple and easy to understand, the content of the information should not
be too long, information should be genuine and unbiased, information given on the leaflet should
be most favorable as per patient requirement. Emphasis must be made on avoiding selfmedication, sharing of medicines and the reader should be advised to use medicines only with
medical advice. (24)
Design, readability and layout of the leaflet are also important. This is assessed by means of
Flesch reading ease score and BALD criteria. The content has to be validated by a team who is
an expert in the topic. A good patient information leaflet will have good scores, which will allow
the patient to understand the content in the leaflet, which in turn would help them with
improving the knowledge and having a positive attitude towards disease management. (24)
Various researches have investigated on the impact of written communication on knowledge and
other therapy programs. Clark and Bayley observed in their studies that a "programmed
instruction" booklet led to more knowledge than a handout or no written-information control. (25)
The importance of leaflets and single page sheets to increase education in patients about drug
therapy have also been discussed in various other studies.(26-27)
A research conducted by Livingstone et al. in a community pharmacy found out that patients
when counseled with PILs, 65 percent of patients were able to recollect information about their
drugs compared to 30 percent of patients previously without education and PIL on their drugs. (28)
Gibbs et al. have shown in their studies that PIL complementing a verbal advice greatly
improved the level of knowledge in 67 percent of the patients in recognizing pros and cons of
medications after education compared to 40 percent of patients at time of admission. (29)
Another way to patient aid is through SMS reminders. Adherence to medical appointments and
taking medication can be improved with the help of SMS and Email remainders. Huges L et al
conducted a study that in which 92% of the patients had mobile phone access. A large number of
the patients responded in a positive way to receive appointment reminders and a quarter of
patients to receive medication reminders. Since majority of people had access of mobile phones
it was an easier method to give a reminder about their follow up reminders. (30) With the
establishment of mobile network services with cheaper cost and higher coverage more people are
making use of information and communication technology (ICT) such as email and SMS text
messaging. (31)
Most of the patients with RA does not meet the recommendations of moderate to vigorous
physical activity (MVPA) and spend a higher proportion of their waking hours sitting than the
general population (71 % and 62 % respectively of awake hours). Sedentary behavior increases
the risk of cardiovascular disease, premature death, cardio-metabolic biomarkers and certain
types of cancer. Means to decrease sedentary activity includes sending the patient SMS
reminders about their disease, and lifestyle modifications. This encourages people to make
behavioral changes to improve their health. (32)
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There is a wide variety of digital media such as social networking, online videos, animations,
interactive and personalized websites or recorded audios/videos. They provide a huge advantage
as they can deliver health related information to the patient at their ease at a time and place
chosen by the patient. With the fast upcoming of mobile phones and other technology, there are
many studies to observe if the digital media can serve as an adjunct to patient care. (33)
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5. METHODOLOGY

Study Site: The study was conducted in general medicine wards and orthopedics wards of
Kasturba hospital.
Study design: Randomized controlled study .
Study period: 6 months
Sample Size: 30 patients
Ethical Approval: Protocol for this study was approved by the Institutional Ethical Committee
of Kasturba Hospital, Manipal.(IEC/ 584/2019) ( APPENDIX I)
Study criteria: The study group comprised of patients admitted in the general medicine wards
and orthopedics wards who met the following criteria during the study period:
Inclusion criteria:
Patients with confirmed diagnosis of Rheumatoid Arthritis according to 2010 ACR/EULAR
Classification Criteria for Rheumatoid Arthritis admitted in General Medicine and Orthopedic
wards of Kasturba Hospital, Manipal.
Patients above 18 years of age, irrespective of gender.
Patients willing to participate in the study.
Exclusion criteria:

Patients not willing to participate

Patients whose diagnosis is not confirmed
Hepatic and Renal impairment
Pregnant and lactating women

HIV or immunocompromised patients at an unacceptable risk
Patients who don’t own phones for digital media group

Data source:
The study population broadly represents the South Indian population. All the necessary and
relevant data were obtained from the medical records and interviews of patients diagnosed with
Rheumatoid arthritis.
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Study materials:
Participant Information Sheet (PIS) - Used to provide necessary details (purpose,
benefits/risks, procedure) regarding the study. (APPENDIX IIa, IIb)
Informed Consent Form - An Informed consent form in Kannada or English was obtained from
each participant before study initiation. (APPENDIX IIIa, IIIb)
Case Report Form (CRF) - A form containing various items were used to assess the
information of the patients who had rheumatoid arthritis. (Physician information, demographic
information, medical history, social history, occupational history, diagnostic parameters,
treatment parameters, and outcomes). (APPENDIX IV)
Operation modality

The study was carried out in 6 main stages:
STAGE 1: Designing prototype Patient information leaflets (PILs)
Leaflets were prepared by referring to primary, secondary and tertiary sources such as
Arthritis.org,[37] American College of Rheumatology,[38], Australian Rheumatology
Association,[39] Arthritis Care, [40] Today’s Dietitian, [41] and various articles related to patient
education on rheumatoid arthritis respectively. Following which, standard prototype leaflets were
designed keeping in consideration, the Flesch Reading Ease (FRE) and Flesch-Kincaid Grade
Level (FK-GL) scores by using MS Office 2007. The leaflet content includes information about
the disease; drugs used in the management of RA and lifestyle modifications.
Leaflet
Disease
General Drug
Methotrexate
Sulphasalazine
Leflunomide
Hydroxychloroquine
Corticosteroids
Lifestyle

FRE Score
70
100
69.5
66.3
73.8
63.3
74.1
71.6

FK-GL Score
5.4
0
5.6
6.3
5.5
6.5
5.3
5.6

Table 4: FRE and FK-GL scores
Scale for FRE: Very easy (90-100), Easy (80-89), Fairly easy (70-79), Standard (60-69), Fairly
difficult (50-59), Difficult (30-49) and Very confusing (0-29).
FK-GL: Number of years of education required to understand the text.[42]
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STAGE 2: Validation of the PILs

The designed leaflets were then validated to ensure their applicability, relevance, and accuracy.
Validation procedure followed is as follows:
1. Experts in the field of rheumatoid arthritis including 2 physicians and academic pharmacists
were consulted to validate the PILs and provide feedback.
2. All required modifications were made in order to improve the scores of the leaflet.

3. After the contents of English PILs were validated, the leaflets were then translated
into Kannada with the help of experts familiar with the language and medical terminologies.
4. An expert physician familiar with Kannada language further validated the translated leaflets.

Designing
prototype
leaflets

Consulting
experts

Making
modifications

Re- calculating
FRE

Figure 1: Flowchart depicting Validation of PILs
STAGE 3: Data collection

1. Data of 30 patients was collected based on inclusion and exclusion criteria.

2. After the informed consent was taken, the participant informant sheet was given.
3. The patient’s pain score was recorded using a visual analogue scale.

4. The patient and/or patient party was asked 20 questions, divided in 8 categories to assess the
functional capacity of the patient such as dressing/grooming, arising, reach, grip, walking,
eating, hygiene, and daily activities.
5. The patient was further asked 10 questions in order to assess their knowledge regarding the
disease, drugs and lifestyle modifications with respect to their condition.

6. After obtaining their baseline knowledge, leaflets were administered based on the group that
the patient falls in, determined by simple randomization using Quickcals- Graphpad
software:




GROUP 1: General drug leaflet
GROUP 2: Disease, Drugs and Lifestyle leaflet
GROUP 3: Disease, Drugs and Lifestyle leaflet and SMS reminders.

7. The patients were counseled according to their grouping and asked to read the leaflets.

8. The same 10 questions were asked again to determine any improvement in patient’s ledge
and understanding, post the counseling session and leaflet administration.
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9. Data were simultaneously recorded on printed copies of CRFs, HAQ questionnaire
(APPENDIX Va, Vb) sheets and pre and post knowledge assessment questionnaire
(APPENDIX VI a, VI b) sheets.
STAGE 4: Data entry

1. The collected data was checked for aberrancies and collated thereafter.
2. It was then entered into MS Excel and re-checked for duplications.
STAGE 5: Evaluation & analysis

The data entered was analyzed based on demographic information, clinical characteristics of
and markers of RA, physical disability assessment, prescription pattern and various counseling
techniques.
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6. RESULTS

6.1 Demographic Overview

A prospective pilot study was conducted in Medicine and Orthopedic wards of Kasturba hospital,
Manipal, comprising of n=30 RA patients and their demographic characteristics were
determined.
Basic demographic characteristics of RA patients

N=30

Patients demographic characteristics
Mean age ±SD in years
Male sex, n (%)
Female sex, n (%)
Non-Alcoholic, n (%)
Non-Smoking, n (%)

59.14 ± 16.19
3 (10%)
27 (90%)
30 (100%)
30 (100%)

Patients clinical characteristics
Duration of RA, Mean ± SD in years
Morning stiffness, Mean ± SD in hours

10.50 ± 13.34 years
1.14 ± 0.75 hours

Severity assessment
ESR, Mean ± SD
CRP, Mean ± SD
SJC (0-28), Mean ± SD
TJC (0-28), Mean ± SD
DAS28, Mean ± SD
HAQ (0-4), Mean ± SD
VAS Pain (VAS 100mm), Mean ± SD

57.18±34.24mm/hr
88.57 ± 87.45 mg/dl.
7.50 ± 9.95
11.57 ± 9.98
5.64 ± 1.65
1.80 ± 0.85
55.67 ± 27.50

ESR: Erythrocyte sedimentation rate, CRP: C-reactive protein, SJC: Swollen joint counts, TJC:
Tender joint counts, DAS28: 28 joint disease activity score, HAQ: Health Assessment
Questionnaire, VAS: Visual analogue scale
Table 5: Demographic Overview
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6.2 Sex
Among n=30 patients
tients enrolled in the study, 3 (10%) were male and 27 (90
(90%)
%) were female. This
shows majority of subjects in the study were female. There was 1 male in group A and 2 males in
group C and no males in group C.

Sex Distribution
10%
male

female

90%

Figure 2: Sex Distribution

Percentage

6.3 Age
Among n=30 patients, majority of the patients fell under the age group of 51-70
70 years (46.7%)
followed by age groups >71 years (26.7%), 331-50 years (13.3%), 18-30
30 years (13.3%).
(13.3

50
45
40
35
30
25
20
15
10
5
0

AGE

46.7
26.7

13.3

13.3

18-30

31-50

51-70

Age Range in years

Figure 3: Eliciting ages of all patients

> 71

24

p
e
r
c
e
n
t
a
g
e

AGE

70.0
60.0
50.0
40.0
30.0
20.0
10.0
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37.536.4

25.0

18.2
12.5
9.1

9.1

18-30

63.6

9.1

31-50

51-70

36.4

25.0
18.2

A
B
C

>71

Age range in years

Figure 4 : eliciting age of patients in different groups
6.4 Occupation

Among n=30 patients, majority of them were housewives n=20 (66.7%) followed by others
given in the figure below.
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70.0
60.0
50.0
40.0
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20.0
10.0
0.0

Occupation

66.7

3.3

3.3

3.3

3.3

3.3

3.3

3.3

3.3

3.3

3.3

Occupation

Figure 5: Occupation
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Group

Occupation

N (%)

A

Housewife

9 (81.8%)

B

Retired hotel worker
Housewife

1 (9.1%)
4 (50%)

Company employee

1 (9.1%)

Airtel Promoter

1 (9.1%)

Business
Auto driver
Manager in educational dept
Retired
Housewife

C

1 (12.5%)
1 (12.5%)
1 (12.5%)
1 (12.5%)
6 (54.5%)

Clerical job in bank
Postal dept
Shop worker

1 (9.1%)
1 (9.1%)
1 (9.1%)

Table 6: Occupation of patients in different groups
6.5 Education

Among n=30 patients, majority were illiterate (45.5% in Group A, 12.5% in group B and 54.4%
in group C), followed by others given in the figure below.

60
50
40

EDUCATIONAL STATUS
50

45.5 45.5

37.5

30
20

9.1

10
0

A

27.3

12.5

B
illiterate

54.5

10th std

18.2

C
college degree

Figure 6: Educational Status
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6.6 Clinical characteristics of RA
6.6.1 Duration of RA

Among n=30 patients, the duration of RA for most of the patients were between 3-5 years
(26.7%), followed by >12 years (16.7%), 0-2 years (13.3%), 9-11 years (10%), 6-8 years (6.7%).

DURATION OF RA

30

26.7

Percentage

25
20
15
10

13.3

0

10

6.7

5

0-2 years

3-5 years

16.7

6-8 years

9-11 years

>12 years

Duration of RA in years

Figure 7: Duration of RA

6.6.2 Classification of RA

Gender wise distribution of rheumatoid factor (RF) among RA patients

Rheumatoid factor

Among n=30 patients, 2 male patients and 14 female patients tested positive for rheumatoid
factor, where as 1 male and 7 female had negative rheumatoid factor. RF for 6 patients were not
specified.

16
14
12
10
8
6
4
2
0

GENDER WISE DISTRIBUTION OF RF
14

7

2

1
male

Rheumatoid factor positive

female
Sex

Rheumatoid factor negative

Figure 8: Gender wise distribution of RF
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6.6.3 Co-morbidities

Among n=30 patients, 26 (87%) had presence of co-morbidities whereas 4 (13%) did not have
co-morbidities.

CO-MORBIDITIES
Present

Absent

13%

87%

Figure 9: Co-morbidities

Sno: Comorbidities

No: of patients (%)

2

1

Hypertension
Anemia

5 (16.7%)

3

Hypothyrodism

5 (16.7%)

5

Gastritis

4
6
7

10 (33.3%)

Diabetes mellitus

5 (16.7%)

Lower Respiratory Tract Infection

3 (10%)

3 (10%)

Cerebrovascular accident

2 (6.7%)

9

Depression

2 (6.7%)

11

Osteoarthritis

8
10
13

Interstitial lung disease
Vit D deficiency

Henoch schontein syndrome

2 (6.7%)
2 (6.7%)

2 (6.7%)

1 (3.3%)
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14

Ischemic Heart Disease

16

Splenic cysts

15
17
18
19
20
21
22
23
24
25
26
27

1 (3.3%)

Peripheral neuropathy

1 (3.3%)

Cellulitis

1 (3.3%)

leptospirosis

1 (3.3%)

1 (3.3%)

parkinsonism

1 (3.3%)

Addisons disease

1 (3.3%)

Scrub typhus

1 (3.3%)

Acute adrenal insufficiency

1 (3.3%)

Nonalcoholic fatty liver disease

1 (3.3%)

Chronic diverculosis

1 (3.3%)

Metabolic encephalopathy

1 (3.3%)

Acute respiratory distress syndrome 1 (3.3%)
Urinary tract infection

1 (3.3%)

Table 7: Comorbidities
6.6.4 Morning stiffness

Among n=30 patients, 9 patients who tested positive for RF complained of morning stiffness,
where as 6 patients who tested negative for RF did not complain of presence of morning
stiffness. Data for the other patients are not known.
6.7 Markers of RA
6.7.1 Erythrocyte Sedimentation Rate (ESR)
The Mean ESR value was found to be 57.18 ±34.24 mm/hr. Among n=30 patients, Mean ESR
value among male was 62.33 ±34.82 mm/hr and among female was 56.56 ± 34.85 mm/hr. 18
patients had high ESR values.
6.7.2 C-reactive protein (CRP)
The Mean CRP value was found to be 88.57 ± 87.45 mg/dl. In group A 7 patients had high CRP
levels. Group B had 6 patients with high CRP levels. Group C had 6 patients with high CRP
levels. Data for the other patients are not known.
6.8 Clinical severity assessment
DAS-28 is used for assessment of disease activity in RA patients by combining 28 TJC, 28 SJC,
ESR and General health assessment using visual analogue scale (VAS).
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6.8.1 Tender joint count (TJC) and swollen joint count (SJC)
Among n=30 patients, mean TJC was found to be 11.57 ± 9.98 and the mean SJC was 7.50 ±
9.95. For RF positive patients (n =16) the mean TJC and SJC was found to be lower than RF
negative patients. (n= 8)
Mean TJC for RF positive patients was 11.73 ± 10.81 and mean TJC for RF negative patients
was 14.50 ± 9.24.
Mean SJC for RF positive patients was 5.80 ± 10.41 and mean SJC for RF negative patients was
11.38 ± 10.30.
6.8.2 DAS28
Based on the Disease activity score, RA patients were categorized into four groups: High disease
activity (>5.1), Moderate disease activity (3.2-<5.1), Low disease activity (2.6 - 3.2) and
Remission (0 - <2.6). Among n=30 patients, 17(56.7%) fell under high activity, 10(33.3%) under
moderate activity, 0 under low activity and 1(3.3%) under remission. Data for the other patients
were not known. Mean DAS28 was found to be 5.64 ± 1.65.
DAS

N(%)

Mean ± SD

10(33.3%)

4.24 ± 0.47

High disease activity (>5.1)

17(56.7%)

Low disease activity (2.6 - 3.2)

-

Moderate disease activity (3.2-<5.1)
Remission (0 - <2.6)

1(3.3%

Table 8: Categorizing Patients with respect to DAS28

6.69 ± 1.09
-

1.80

6.9 Physical disability assessment
Among n=30 patients, mean HAQ was found to be 1.18 ± 0.87. After 3 months, the
questionnaire was administered again and the mean HAQ was found to be 1.01 ± 0.89. The
Mean VAS score was 55.67 ± 27.50. After 3 months, mean VAS score was found to be 44.3 ±
24.45.
7.0 Prescription pattern of RA patients
7.0.1 Prescription pattern of DMARD

Drug utilization was analyzed during this study. Among n=30 patients, 22 (73.3%) patients
received DMARDs and 8 (26.7%) patients did not. Methotrexate (MTX) was widely prescribed
in 16(53.3%) patients, followed by Hydroxychloroquine (HCQ) 15 (50%), Sulfasalazine
(SSZ)10 (33.3%)and Leflunomide (LEF) 2 (6.7%). Among combination therapy MTX+HCQ
combination was preferred over other combinations and was given in 7(23.3%) patients followed
by HCQ+MTX+SSZ combination in 6(20% patients. Biologicals were not prescribed in the
study population.
NSAIDS and other analgesics were prescribed in 14 (46.7%) patients for pain management.
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Prednisolone was most frequently used for its anti inflammatory and immunosuppressive
properties and was prescribed in 16 (53.3%) patients.

S.No
1
2
3
4
5
6
7
8
9

DMARDS
combination
Single
7 (23.3%)

Non Biological DMARDs

No.Of patients
(n=30) (%)
2 (28.5)

Methotrexate (MTX)

Hydroxychloroquine (HCQ)

2 (28.5)

Leflunomide (LEF)

0

Sulfasalazine (SSZ)

3 (42.8)

Methotrexate + Sulfasalazine (MTX+SSZ)

1 (3.3)

Methotrexate + Leflunomide (MTX+LEF)

1 (3.3)

Dual
9 (30%)

Methotrexate + Hydoxychloroquine (MTX+HCQ)

Triple
6 (20%)

Hydroxychloroquine+ Methotrexate+ Sulfasalazine
(HCQ+MTX+SSZ)

7 (23.3)
6 (20)

No DMARDs

Others

8 (26.7)

NSAIDs alone
Corticosteroids+ NSAIDs

14 (46.7)
6 (20)

Table 9: Prescription pattern of DMARD combinations
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26.7

23.3
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6.7

3.3

3.3

Figure 10: Prescription pattern of DMARD combinations
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7.1 Counseling techniques

The study population was randomly grouped into three categories by simple randomization using
Quickcals- Graphpad software. Among n=30 patients, 11 (36.7%) patients fell under category A,
8 (26.7%) in category B and 11 (36.7%) in category C. Each category received a separate type of
counseling technique. Improvement in patient’s knowledge, pain and physical disability were
assessed with respect to the counseling technique.
Group A

 Counselling by consultant
doctor and the nurse
 General drug leaflet

Group B

 One to One counselling by
clinical pharmacist
 Drugs, Disease, Lifestyle
Leaflets
Table 10: Counseling techniques

Group C

 One to One Counselling by
clinical pharmacist
 Drugs, Disease, Lifestyle
Leaflets
 Text message Reminders

7.1.1 Knowledge assessment with respect to counseling

During the study, improvement in patient’s knowledge was assessed by administering a set of 10
questions to be answered by the patients before and after the counseling session. The responses
were totaled and scored as follows: very poor understanding (1-1.9); poor understanding (2-2.9);
moderate understanding (3-3.9); good understanding (4-4.9); very good understanding (>5).
For all the groups, the understanding after counseling improved from moderate to good
understanding. Group C demonstrated a greater difference in understanding.
Patient Group

Pre assessment of
knowledge

Post assessment of
knowledge

A

Mean ±SD

3.15 ± 0.68

3.68± 0.48

B

Mean ±SD

3.65 ± 1.04

4.05±0.76

C

Mean ±SD

3.51 ± 1.21

4.12 ± 0.51

Table 11:Knowledge assessment with respect to counseling
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7.1.2 Pain VAS with respect to counseling

During the study, patient’s pain score was recorded. After 3 months, follow up pain score was
recorded to determine any difference as a result of the counseling recommendations.
Group C demonstrated greater decrease in pain score in comparison to other groups.
Patient Group

Pre Pain VAS

Post Pain VAS

A. Mean ±SD

62.73 ± 24.94

49.09 ± 25.48

B. Mean ±SD

46.25 ± 21.34

46.25 ±25.60

C. Mean ±SD

55.45 ± 33.58

38.18 ± 23.59

Table 12: Pain VAS with respect to counseling
7.1.3 Physical disability with respect to counseling

During the study, patients HAQ score was recorded before the counseling session. After 3
months, follow up HAQ score was recorded to determine any difference as a result of the
counseling recommendations.
Group B demonstrated greater difference in HAQ score in comparison to other groups.
Patient Group

Pre HAQ

Post HAQ

A. Mean ±SD

1.47 ± 0.87

1.31 ± 0.90

B. Mean ±SD

0.98 ± 0.89

0.73 ± 0.85

C. Mean ±SD

1.03 ± 0.84

0.92 ± 0.89

Table 13: Physical disability with respect to counseling
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7. DISCUSSION
Education for individuals with RA is vital, since it enables them to adjust and adapt with the
impacts of disease and treatments. (34) Inadequate knowledge of the matter directly influences
patient's reaction to treatment and acquiring a satisfactory health-related quality of life. (35)
The study by Khoury Vet al highlighted the importance of educating patients with RA using
various techniques including leaflets and digital media for safe and effective use of the
prescribed drugs. (43)
8.1 Comparing three counseling interventions
In this study, various counseling techniques provided to patients with RA were studied with
respect to the level of knowledge gained, improvement in pain score, as well as HAQ score.
Patients understanding at baseline period showed low mean values of 3.15 ± 0.68 (A), 3.65 ±
1.04 (B), and 3.51 ± 1.21 (C); in comparison to the increased mean values post counseling 3.68
± 0.48 (A), 4.05 ± 0.76 (B), 4.12 ± 0.51 (C) (table 9).These results demonstrated that
pharmaceutical care counseling with the aid of leaflets provided to group B and C were
increasingly useful in improving patients understanding regarding their condition as opposed to
the control group A.
Pain score of the patients were recorded during the study and after 3 months to determine
whether there was any improvement in the follow up pain score as a result of the counseling
recommendations. Group C demonstrated greater decrease in pain score 55.45 ± 33.58 to 38.18
± 23.59 (table 10).
These outcomes resemble those of authors such as Senara Set al who found a decrease in
disability, pain, and other clinical parameters after the utilization of educational intervention in
patients with RA. (34) In addition, a study by Lindroth Yet al proposed that the education
programs should be incorporated in the RA treatment. (36)
8.2 Drug utilization, disease activity and quality of life

MTX was widely prescribed as monotherapy or in combination with other DMARDs in 16
(53.3%) patients, followed by HCQ in 15 (50%) patients (table 6). Among combination therapy
MTX+HCQ combination was preferred over other combinations and was given in 7(23.3%)
patients followed by HCQ+MTX+SSZ combination in 6 (20%) patients. Given that the standard
DMARDs prescribed in all groups were the same, the improvement in patient’s condition could
be due to the educational program.
Mean DAS28 was found to be 5.64 ± 1.65 and 17 (56.7%) patients fell under high disease
activity. During the study, patients HAQ score was also recorded before the counseling session.
After 3 months, follow up HAQ score was recorded to determine any difference as a result of the
counseling recommendations. Group B demonstrated greater difference in HAQ score in
comparison to other groups.
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LIMITATIONS
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8. LIMITATIONS
1. Language barrier

2. Missing reports or lack of documentation if the patient gets transferred from another hospital
3. Follow up is time consuming

4. Interventions of forwards and messages may not be always acceptable to people and may
disturb them.
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9. CONCLUSION

The study demonstrated that pharmaceutical care counseling with the aid of leaflets as well as
text message reminders were well received by the patients resulting in improved understanding
regarding their condition as well as improvement in the pain and HAQ scores. This had a
positive impact on the quality of life of RA patients
Majority of patients fell under high disease activity and MTX was widely prescribed as
monotherapy or in combination with other DMARDs followed by HCQ. Among combination
therapy MTX+HCQ combination was preferred over other combinations.
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FUTURE DIRECTIONS
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10. FUTURE DIRECTIONS
1. Further studies can be done in large multicenter hospitals with cultural variations
2. Patient information leaflets can be translated to other languages
3. This study was conducted only in Manipal and hence these results do not represent the
whole India. In near future, more such studies should be carried.
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APPENDIX I: CTRI REGISTRATION NO. & IEC CERTIFICATE
CTRI REGISTRATION NUMBER: CTRI/2018/10/016139
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APPENDIX ll a: PIS (ENGLISH)
PARTICIPANT INFORMATION SHEET

Project title: “To Study Disease Activity and various Counseling Techniques in Rheumatoid
Arthritis patients”
IEC No.:
Sponsor Name: NA
Language: English
Principal Investigator: Shabnam Amerali
Designation: Student
Hospital: Kasturba Hospital, Manipal
Mobile number: 9741520873

Please read this form carefully. If you don’t understand the language or any information in this
document, please discuss with study doctor. Your participation in this study is voluntary, and you
can enquire about all details before giving your written consent to participate in this study.
1. Introduction to the research study:
You are invited to participate in this study because you have Rheumatoid Arthritis. This study
involves the use of a drug as prescribed by your treating physician. This is an Interventional study.
2. Purpose of the study:

1. The objective of this study is to assess three counseling interventions
2. To study Drug utilization and Disease Activity in Rheumatoid Arthritis patients
3. Who can take part:
Inclusion criteria:




Patients with confirmed diagnosis of Rheumatoid Arthritis
Patients who are above 18 years of age irrespective of gender
Patients willing to participate in the study






Patients whose diagnosis is not confirmed
Hepatic and Renal impairment
Pregnant and lactating women
HIV or immunocompromised patients at an unacceptable risk

Exclusion criteria:
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Patients admitted in departments other than Medicine and Orthopedic
Patients who don’t own phones for digital media group

4. Information about the study (as a whole) :


No. of patients expected to participate / sample size : TOTAL 294 ( 98 in each group)

5. What will happen to you (the individual participant) during the study :

Patients will be randomly grouped into 3 categories receiving three separate counseling
techniques– Randomized Controlled trial.
Number of visits to the hospital: Only Once in 3 monthS during the study period
Upon visit, Patients will be asked regarding their current disease and medications, any past
histories and counseled according to their grouping regarding their drugs, disease and lifestyle.
They will also be asked to fill Health Assessment Questionnaire (HAQ).
Counseling will be done on patients visit to the hospital only. Patients will not be asked for any
special visits to the hospital for the study.

Group 1 shall receive the standard care which involves routine counseling provided at the
hospital (control group). They will also receive any additional general counseling regarding the
drugs in form of leaflets.


Group 2 shall receive counseling regarding disease, drug and lifestyle. This will be achieved
through one to one counseling and by means of patient information leaflets.


Group 3 shall receive counseling as stated in Group 2 along with text message for follow up
reminders.
For all patients regardless of the grouping,
-HAQ will be used to evaluate patients overall global health assessment, Pain VAS (Visual
Analogue Scale) and Physical Function assessment.
-The DAS will be used to measure disease activity in RA patients.

A feedback will be collected after three (3) months from the participants to assess whether the
counseling technique improved their understanding of the disease.

State the amount of time required by the individual participant for each phase of the
study, with a clear statement of the total duration of the study: 15-20minutes will be required by
each participant to fill the questionnaire and to attend the counseling session.
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6. Your (the individual participant) role/responsibility in the study:





Provide accurate information whenever asked.
Inform the study doctor about any problem/side effects experienced during the study.
Follow the investigators instruction.
If you want to discontinue from the study, study doctor to be informed.

7. What are the risks?


Extra time needing to be spent for the counselling sessions

Some discomfort and anxiety may be experienced by a few patients while they receive text
messages or undergo counselling
8. What are the potential benefits of participating in the study:

You may or may not get benefit from participating in this study. It is possible that you may get
better, stay the same, or get worse. If you take part in this study you may help other patients
with Rheumatoid Arthritis by contributing to the better understanding of the disease.
9. What are the alternative treatments available:
The alternative is to not participate and standard counselling will be done by the consultant
doctor.
10. Cost of participating in the study:
There are no costs related to participation in this study.

11. Compensation for injury:
If a medical problem arises during this research study as a direct result of the study procedure,
the study doctor will be responsible for making sure that proper medical care is provided to you.
If you suffer any physical/mental injury or illness as a direct result of the properly performed
study procedures, sponsorer will reimburse you for reasonable medical expenses that you incur
to treat the injury or illness
12. Confidentiality of information:

Information from the study records including your name, address, medical records, results of
tests, study results will be kept confidential and will be reviewed only by authorized personnel
from the sponsor or their representative, Ethics Committee or regulatory bodies. The data will
not be made available to another individual unless you specifically give permission in writing.
Information and results from this study may be presented at meetings or published in journals
without including your name and personal identifications. No reference will be made in oral or
written reports which could link you to the study.
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13. New information about the study:

Any new information available during the course of the study will be informed to you if it has
relevance to your decision regarding continuing in the study. Results of your participation will be
disclosed to you if you indicate your desire for it.
14. Voluntary participation:

Your participation in this study is voluntary; you may decline to participate at any time and you
need not give any reason for the same, and such withdrawal shall be without penalty and without
loss of benefits to which you are otherwise entitled. If you withdraw from the study prior to its
completion, you will receive the usual standard of care for your disease, and your non
participation will not have any adverse effects on your subsequent medical treatment or
relationship with the treating physician.
If you withdraw from the study before data collection is completed, your data collected until you
indicated withdrawal will be used in the study report. Sponsor or the investigator may stop the
research or your participation in it at any time for some or other reason without your permission.
15. Whom to contact in case of any questions:

If you have any questions about the informed consent process or your rights as a participant, you
may contact the Member Secretary of the Kasturba Medical College and Kasturba Hospital Institutional Ethics Committee at Room 22, Ground floor, KMC Faculty Rooms, adjacent to KMC
Administrative Block, Kasturba Medical College, Manipal - 576104. Phone: 0820 29 33522.
Timings: 9 : 00 AM to 5 : 00 PM.
If you have any questions about this form or any study related issue, you may also contact the
following person.
Name : Dr. GirishTunga
Address : Department of Pharmacy Practice
Manipal College of Pharmaceutical Sciences
Manipal, Karnataka, 576104
Telephone No: 9880151127
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APPENDIX III a: ICF (ENGLISH)
INFORMED CONSENT FORM
Project title: To study Disease Activity and various Counselling techniques in Rheumatoid Arthritis patients
I confirm I have read the Participant Information Sheet for the above study and its contents were explained
and I have had the opportunity to ask questions and received satisfactory answers.
I understand that my participation in the study is voluntary and that I have the right to withdraw at
any time without giving any reason, without my medical care or legal rights being affected.

I agree to take part in the above study. I confirm that I have received a copy of the Participant Information
Sheet along with this signed and dated informed consent form.
Name of the Research Participant :
Age of the Research Participant :

Address of the Research Participant :
Occupation :

Annual Income of the Participant :

Name & address of the nominee(s) and his relation to the Participant :

_________________________________________________________________________
__________________________
Signature of the research subject

_________
Date

__________________________
Name & Signature of the witness

_________
Date

_______________________________________________
Name & Signature of the person explaining the consent

_________
Date
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APPENDIX lll b: ICF (KANNADA)

58

APPENDIX IV : CRF
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APPENDIX Va: Health Assessment Questionnaire
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APPENDIX V b: Health Assessment Questionnaire
Kannada
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APPENDIX VI a: Pre and post assessment of knowledge questionnaire English
WE WOULD LIKE TO KNOW YOUR UNDERSTANDING OF THE DISEASE YOU ARE
SUFFERING FROM, BEFORE AND AFTER THE COUNSELLING WE HAVE PROVIDED.
CHECK THE OPTION THAT MATCHES YOUR ANSWER
1.






I know what is Rheumatoid Arthritis
Strongly Disagree
Somewhat Disagree
Neither Agree or Disagree
Somewhat Agree
Strongly Agree

2.






I am aware of the symptoms of this disease
Strongly Disagree
Somewhat Disagree
Neither Agree or Disagree
Somewhat Agree
Strongly Agree

3.






I am taking my medications everyday
Strongly Disagree
Somewhat Disagree
Neither Agree or Disagree
Somewhat Agree
Strongly Agree

4.






I have basic knowledge regarding the medications I am taking
Strongly Disagree
Somewhat Disagree
Neither Agree or Disagree
Somewhat Agree
Strongly Agree

5.






Exercise helps reduce my joint stiffness and ease my pain
Strongly Disagree
Somewhat Disagree
Neither Agree or Disagree
Somewhat Agree
Strongly Agree
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6.






I exercise at least three times a week
Strongly Disagree
Somewhat Disagree
Neither Agree or Disagree
Somewhat Agree
Strongly Agree

7.






I am aware that excessive sugar intake will aggravate my condition
Strongly Disagree
Somewhat Disagree
Neither Agree or Disagree
Somewhat Agree
Strongly Agree

8.






I take extra care when it comes to my lifestyle and eating habits
Strongly Disagree
Somewhat Disagree
Neither Agree or Disagree
Somewhat Agree
Strongly Agree

9.






A healthy diet including fruits and vegetables will be beneficial for my condition
Strongly Disagree
Somewhat Disagree
Neither Agree or Disagree
Somewhat Agree
Strongly Agree

10. Early treatment reduces chances of having permanent joint damage
 Strongly Disagree
 Somewhat Disagree
 Neither Agree or Disagree
 Somewhat Agree
 Strongly Agree
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APPENDIX VI b: Pre and post assessment of knowledge questionnaire
Kannada
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